Navigation Links
It's not all genetic: Common epigenetic problem doubles cancer risk in mice

In experiments with mice, a team of scientists from the United States, Sweden and Japan has discovered that having a double dose of one protein is sufficient to change the normal balance of cells within the lining of the colon, thereby doubling the risk that a cancer-causing genetic mutation will trigger a tumor there. Roughly 10 percent of people have this double protein dose as well.

In the Feb. 24 online version of Science, the researchers report that mice engineered to have a double dose of insulin-like growth factor 2 (IGF2) develop more so-called precursor cells within the lining of the colon than normal mice. When these mice also carried a colon-cancer-causing genetic mutation, they developed twice as many tumors as those with normal IGF2 levels, the researchers report.

"Both clinically and scientifically, this discovery should expand attention in colon cancer research to earlier events, situations present well before tumors appear," says the study's leader, Andrew Feinberg, M.D., M.P.H., professor of medicine and director of the Center for Epigenetics in Common Human Disease at Johns Hopkins.

"In the mice with a double dose of IGF2, everything is pretty normal except for the extra precursor cells," says Christine Iacobuzio-Donahue, M.D., assistant professor of pathology and oncology. "But when the genetic mutation is present, too, we found a clear cost for what otherwise appears to be a benign effect of extra IGF2."

The team's analysis of colon tissue samples from a dozen or so Johns Hopkins patients with suspected colon cancer suggests that IGF2's effect in people may be similar, the researchers report. A larger study of samples from patients with and without suspected colon cancer is underway, Feinberg notes.

In the mice -- as well as in about 30 percent of colon cancer patients and 10 percent of the general population -- the extra IGF2 stems not from a genetic problem, or mutation, but an "epigenetic" problem that im
'"/>

Source:Johns Hopkins Medical Institutions


Page: 1 2 3

Related biology news :

1. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
2. Men Estimate Mens Risks Of Common Disorders Higher Than Women Do, And Vice Versa
3. Use of Antibiotics for Acne May Increase Risk of Common Illness
4. Common viruses may cause cancer
5. Common alternative treatment for liver disease is found to be ineffective
6. Common molecular signature identified in solid tumors
7. Common bacteria pirate natural mechanism to get inside cells
8. Commonly used antidepressants may also affect human immune system
9. Common practices at petting zoos put visitors at risk
10. Common enzyme is a key player in DNA repair
11. Common molecular signature identified in solid tumors
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: not all genetic Common epigenetic problem doubles cancer risk mice

(Date:8/20/2015)... OXFORD, CT ., Aug. 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... wallet, announces it has joined The Smart Card Alliance ... the Smart Card Alliance and the Smart Card Alliance ... and visibility to industry peers and thought leaders promoting ...
(Date:8/18/2015)... N.J. , Aug. 18, 2015 /PRNewswire/ ... a key contributor to the Submission Content ... by IRISS, a non-profit forum. Dedicated to the ... provides a neutral platform for industry, vendors, ... share information and work towards a standard ...
(Date:8/17/2015)... Conn. , Aug. 17, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... its new sales campaign for Q4 2015. The new ... marketing team consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ... Marketing Group is a leader in retail driven marketing ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... finding on the brain's role in controlling appetite and ... have shown that reducing levels of fatty acids in ... Their results suggest that restoring fatty-acid levels in the ... The study, published in the January 15th on-line edition ...
... 17 and mouse chromosome 11 offers unique insights into ... a Baylor College of Medicine researcher who participated in ... Nature. , The work represents the first time that ... said Dr. James R. Lupski, vice chair and professor ...
... emit a cocktail of scents when they are attacked by ... cotton leaf worm. , Parasitic wasps use these plant scents ... so that their offspring can feed on the caterpillar. ... from its attacker. In the case of corn, only one ...
Cached Biology News:Study by Einstein researchers could lead to a novel strategy for treating obesity 2Mouse to man: The story of chromosomes 2New possibilities to fight pests with biological means 2
(Date:9/2/2015)... , Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s new ... Companies" to their offering. This ... development of sequencing technologies, and their applications. Current ... as companies developing them. Various applications of sequencing ...
(Date:9/2/2015)... 02, 2015 Research and ... Jain PharmaBiotech,s new report "Gene Therapy - Technologies, ... The markets for gene therapy are difficult to estimate ... and it is marketed in China ... the years 2014-2024. The estimates are based on epidemiology ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... , September 2, 2015 ... BOLT) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, announced today that presentations ... glaucoma will be delivered at the Ophthalmology Futures ... European Society of Cataract & Refractive Surgeons ("ESCRS"), ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... VRML ) announced that on February 22, 2008 it ... indicated the Company is not in,compliance with Marketplace Rule ... $2,500,000 in stockholders, equity; (ii) $35,000,000 in market,value of ... continuing,operations for the most recently completed fiscal year or ...
... SAN DIEGO, Feb. 27 Arena Pharmaceuticals,Inc. (Nasdaq: ... quarter,and full year ended December 31, 2007., Total ... million,compared to $4.7 million in the fourth quarter of ... 2007 were $19.3 million, compared to $30.6,million in the ...
... Feb. 27 DARA BioSciences(TM),(Nasdaq: DARA ) announced ... Board of Directors. Mr. Cochrane was appointed to fill ... and Compensation Committees.,The appointment was effective February 21, 2008., ... Franco, Sr.,commented, "We are pleased that Haywood has joined ...
Cached Biology Technology:Vermillion Receives NASDAQ Notice of Non-Compliance 2Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 2Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 3Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 4Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 5Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 6Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 7Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 8Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 9Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 10Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 11DARA BioSciences, Inc. Announces Appointment of New Director to Board 2
Syd-2 (cL-19)...
... for isolation and affinity purification of ... peptides. Hydrophobic, monodisperse magnetic particles (2.8 ... groups, further surface activation is not ... with optimal orientation for affinity purification ...
ZO-2 (H-110)...
p-Bcl-2 (Thr 74)...
Biology Products: